Received: 1 October 2020
Accepted: 22 January 2021
First Online: 28 January 2021
Ethics approval and consent to participate
: Ethics approval for the study was obtained from the University of New South Wales HREAP G: Health, Medical, Community and Social (HC200190). After reading the respondent information, consent was implied if the person completed the survey and submitted it via the QOR website.
: Not applicable.
: Dr. Holly Seale has previously received funding from drug companies for investigator driven research and consulting fees to present at conferences/workshops and develop resources (Seqirus, GSK and Sanofi Pasteur). She has also participated in advisory board meeting for Sanofi Pasteur. She is a Section Editor for BMC Infectious Diseases. The other authors do not have anything to declare.